Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease

• Published in: Frontiers in microbiology 2023, Vol.14, p.1293300-1293300
• Main Authors: Alruwaili, Yasir, Jacobs, Mary B, Hasenkampf, Nicole R, Tardo, Amanda C, McDaniel, Celine E, Embers, Monica E
• Format: Article
• Language: English
• Subjects: antibiotic; Borrelia burgdorferi; combination; efficacy; Lyme disease; mouse
• ISSN: 1664-302X; 1664-302X
• DOI: 10.3389/fmicb.2023.1293300

Lyme disease (LD) results from the most prevalent tick-borne infection in North America, with over 476,000 estimated cases annually. The disease is caused by which transmits through the bite of Ixodid ticks. Most cases treated soon after infection are resolved by a short course of oral antibiotics. However, 10-20% of patients experience chronic symptoms because of delayed or incomplete treatment, a condition called Post-Treatment Lyme Disease (PTLD). Some persists in PTLD patients after the initial course of antibiotics and an effective treatment to eradicate the persistent is needed. Other organisms that cause persistent infections, such as , are cleared using a combination of therapies rather than monotherapy. A group of Food and Drug Administration (FDA)-approved drugs previously shown to be efficacious against were used in monotherapy or in combination in mice infected with . Different methods of detection were used to assess the efficacy of the treatments in the infected mice including culture, xenodiagnosis, and molecular techniques. None of the monotherapies eradicated persistent . However, 4 dual combinations (doxycycline + ceftriaxone, dapsone + rifampicin, dapsone + clofazimine, doxycycline + cefotaxime) and 3 triple combinations (doxycycline + ceftriaxone+ carbomycin, doxycycline + cefotaxime+ loratadine, dapsone+ rifampicin+ clofazimine) eradicated persistent infections. These results suggest that combination therapy should be investigated in preclinical studies for treating human Lyme disease.